Outpatient Haploidentical Stem Cell Transplantation

Article

The latest episode of the ASTCT Talks episode features a discussion from Andrés Gómez De León, MD, and Perla Colunga, MD, on outpatient haploidentical stem cell transplantation.

In this episode of ASTCT Talks, Andrés Gómez De León, MD, physician at the Universidad Autónoma de Nuevo León Hematology Service in Monterrey, Mexico, and Perla Colunga, MD, a specialist physician in the hematology service of UANL, discuss their paper “Outpatient Haploidentical Stem Cell Transplantation Using Post-Transplant Cyclophosphamide Is Safe and Feasible,” which was published in ASTCT’s Transplantation and Cellular Therapy journal in December.

Tune in

ASTCT Talks is the official podcast of the American Society for Transplantation and Cellular Therapy (ASTCT). We chat with industry leaders from all areas of the blood and marrow transplantation and cellular therapy field, including doctors, physician assistants, pharmacists, nurses, administrators, social workers, and more. Like what you hear? Subscribe to ASTCT Talks and never miss an episode.

Reference

Colunga-Pedraza PR, Gómez-De León A, Rodríguez-Roque CS, et al. Outpatient Haploidentical Stem Cell Transplantation Using Post-Transplant Cyclophosphamide Is Safe and Feasible. Transplant Cell Ther. 2021;27(3):259.e1-259.e6. doi:10.1016/j.jtct.2020.12.006

Recent Videos
Co-hosts Kristie L. Kahl and Andrew Svonavec highlight what to look forward to at the 67th Annual ASH Meeting in Orlando.
A new clinical trial aims to offer a novel allogenic CAR T-cell product for patients with lymphoma closer to home.
Modification of REMS programs may help patients travel back to community practices sooner, according to Suman Kambhampati, MD.
Symposiums and regional meetings may expand knowledge of how to adopt novel CAR T-cell therapies and bispecific antibodies, said Suman Kambhampati, MD.
It can cause thrombocytopenia and diarrhea, which are generally manageable and not too big a deal.
More follow-up data will better elucidate the impact of frontline use of hypomethylating agents in patients with myelodysplastic syndromes.
Greater direct access to academic oncologists may help address challenges associated with a lack of CAR T education in the community setting.
Related Content
Increased Dose of Axatilimab Noted as Tolerable in cGVHD

Increased Dose of Axatilimab Noted as Tolerable in cGVHD

Kristie L. Kahl
December 6th 2025
Article

“Overall, these findings support the safety and feasibility of axatilimab at a dose of 0.6 mg/kg monthly,” said Nosha Farhadfar, MD.

A panel of oncology pharmacists discusses the role of lifileucel in metastatic melanoma and other considerations for using cellular therapy in solid tumors.

Optimizing Care for TILs, Cellular Therapy in Melanoma and Solid Tumors

Brooke Adams, PharmD, BCOP;Natalie Brumwell, PharmD, BCOP;Bryant A. Clemons, PharmD, BCOP
October 6th 2025
Podcast

A panel of oncology pharmacists discusses the role of lifileucel in metastatic melanoma and other considerations for using cellular therapy in solid tumors.

AI revolutionizes palliative oncology by enhancing prognostication, symptom management, and personalized care for patients with hematologic malignancies.

The Role of Artificial Intelligence in Palliative Oncology: Zeroing in on Hematologic Malignancies

Ram Prakash Thirugnanasambandam, MBBS;Ariana Bauer, MD;Christopher D’Angelo, MD
December 3rd 2025
Article

AI revolutionizes palliative oncology by enhancing prognostication, symptom management, and personalized care for patients with hematologic malignancies.

Experts detailed key advances in myelofibrosis, multiple myeloma, and lymphoma at the Society of Hematologic Oncology 2025 Annual Meeting.

Unraveling Key Blood Cancer Takeaways From the 2025 SOHO Meeting

Francesca Palandri, MD, PhD;Sundar Jagannath, MD;Adam J. Olszewski, MD
September 15th 2025
Podcast

Experts detailed key advances in myelofibrosis, multiple myeloma, and lymphoma at the Society of Hematologic Oncology 2025 Annual Meeting.

Tandem CAR T cells targeting mesothelin and MUC16 overcome tumor heterogeneity by targeting one antigen at a time

Tandem CAR T cells targeting mesothelin and MUC16 overcome tumor heterogeneity by targeting one antigen at a time

American Society for Transplantation and Cellular Therapy
November 24th 2025
Article

Researchers have demonstrated that a tandem CAR T cell targeting mesothelin and MUC16 ectodomain is able to outmaneuver tumor heterogeneity, outperforming single target CAR T cells in mixed ovarian and pancreatic models.

Outcomes of haploidentical vs. mismatched unrelated donor HCT with posttransplant cyclophosphamide prophylaxis

Outcomes of haploidentical vs. mismatched unrelated donor HCT with posttransplant cyclophosphamide prophylaxis

American Society for Transplantation and Cellular Therapy
October 31st 2025
Article

Researchers have determined that donor age has a stronger, nonlinear impact on OS vs donor type in allogeneic HCT using posttransplant cyclophosphamide for GVHD prophylaxis, with donor type becoming increasingly relevant in older donors.